MedTrace Logo

A Study to Evaluate Efficacy and Safety of GW117 Tablets in Major Depressive Disorder

NCT06796868 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2025-04-23

No results posted yet for this study

Summary

The study aims to evaluate the efficacy and safety of GW117 Tablets compared to placebo in adults participants with MDD over a period of 8 weeks.

Conditions

  • Major Depressive Disorder (MDD)

Interventions

DRUG

GW117 Tablets

GW117 Tablets 20mg orally once a day

DRUG

GW117 Tablets

GW117 Tablets 20mg\*2 orally once a day

DRUG

GW117 Tablets

GW117 Tablets 20mg\*3 orally once a day

DRUG

Placebo

placebo orally once a day

Sponsors & Collaborators

  • Beijing Greatway Pharmaceutical Technology Co.,Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-07
Primary Completion
2023-09-28
Completion
2023-10-12

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06796868 on ClinicalTrials.gov